FDA Compliance for Peptide Therapy and BPC 157 Holt Law FDA 483 vs. Warning Letter: Compliance Guide Quality Forward New: An FDA decision to place 19 peptides on the unsafe list was supported by numerous documented safety concerns, former officials said. Even though demand for peptide therapies has exploded since then, FDA issued 30 warning letters to telehealth companies for false and misleading claims about compounded GLP 1 products. This marks the second round of enforcement action since the agency's September crackdown on misleading